<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">31493784</PMID><DateCompleted><Year>2019</Year><Month>12</Month><Day>02</Day></DateCompleted><DateRevised><Year>2020</Year><Month>02</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2377</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>1</Issue><PubDate><Year>2019</Year><Month>Sep</Month><Day>07</Day></PubDate></JournalIssue><Title>BMC neurology</Title><ISOAbbreviation>BMC Neurol</ISOAbbreviation></Journal><ArticleTitle>Real world experience of patients with amyotrophic lateral sclerosis (ALS) in the treatment of spasticity using tetrahydrocannabinol:cannabidiol (THC:CBD).</ArticleTitle><Pagination><StartPage>222</StartPage><MedlinePgn>222</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">222</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12883-019-1443-y</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Treatment of spasticity poses a major challenge in amyotrophic lateral sclerosis (ALS) patient management. Delta-9-tetrahydrocannabinol (THC):cannabidiol (CBD) oromucosal spray (THC:CBD), approved for the treatment of spasticity in multiple sclerosis, serves as a complementary off-label treatment option in ALS-related spasticity. However, few structured data are available on THC:CBD in the treatment of spasticity in ALS.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">A retrospective mono-centric cohort study was realised in 32 patients that meet the following criteria: 1) diagnosis of ALS, 2) ALS-related spasticity; 3) treatment with THC:CBD. Spasticity was rated using the Numeric Rating Scale (NRS). Patient's experience with THC:CBD was assessed using the net promoter score (NPS) and treatment satisfaction questionnaire for medication (TSMQ-9) as captured through telephone survey or online assessment.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The mean dose THC:CBD were 5.5 daily actuations (range&#x2009;&lt;&#x2009;1 to 20). Three subgroups of patients were identified: 1) high-dose daily use (&#x2265; 7 daily actuations, 34%, n&#x2009;=&#x2009;11), 2) low-dose daily use (&lt;&#x2009;7 daily actuations, 50%, n&#x2009;=&#x2009;16), 3) infrequent use (&lt;&#x2009;1 daily actuation, 16%, n&#x2009;=&#x2009;5). Overall NPS was +&#x2009;4.9 (values above 0 express a positive recommendation to fellow patients). Remarkably, patients with moderate to severe spasticity (NRS&#x2009;&#x2265;&#x2009;4) reported a high recommendation rate (NPS: +&#x2009;29) in contrast to patients with mild spasticity (NRS&#x2009;&lt;&#x2009;4; NPS: -&#x2009;44). For the three main domains of TSQM-9 high mean satisfaction levels were found (maximum value 100): effectiveness 70.5 (&#xb1;22.3), convenience 76.6 (&#xb1;23.3) and global satisfaction 75.0 (&#xb1;24.7).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">THC:CBD is used in a wide dose range suggesting that the drug was applied on the basis of individual patients' needs and preferences. Contributing to this notion, moderate to severe spasticity was associated with an elevated number of daily THC:CBD actuations and stronger recommendation rate (NPS) as compared to patients with mild spasticity. Overall, treatment satisfaction (TSQM-9) was high. The results suggest that THC:CBD may serve as a valuable addition in the spectrum of symptomatic therapy in ALS. However, prospective studies and head-to-head comparisons to other spasticity medications are of interest to further explore the effectiveness of THC:CBD in the management of spasticity, and other ALS-related symptoms.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Meyer</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-2736-7350</Identifier><AffiliationInfo><Affiliation>Centre for ALS and other motor neuron disorders, Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, corporate member of Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t zu Berlin, and Berlin Institute of Health, Berlin, Germany. thomas.meyer@charite.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ambulanzpartner Soziotechnologie APST GmbH, Westhafenstr. 1, 13353, Berlin, Germany. thomas.meyer@charite.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Funke</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Neurologische Facharztpraxis, Lessingstra&#xdf;e 24, 15745, Wildau, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xfc;nch</LastName><ForeName>Christoph</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Centre for ALS and other motor neuron disorders, Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, corporate member of Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t zu Berlin, and Berlin Institute of Health, Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ambulanzpartner Soziotechnologie APST GmbH, Westhafenstr. 1, 13353, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kettemann</LastName><ForeName>Dagmar</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Centre for ALS and other motor neuron disorders, Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, corporate member of Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t zu Berlin, and Berlin Institute of Health, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maier</LastName><ForeName>Andr&#xe9;</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centre for ALS and other motor neuron disorders, Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, corporate member of Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t zu Berlin, and Berlin Institute of Health, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walter</LastName><ForeName>Bertram</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Centre for ALS and other motor neuron disorders, Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, corporate member of Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t zu Berlin, and Berlin Institute of Health, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thomas</LastName><ForeName>Annett</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centre for ALS and other motor neuron disorders, Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, corporate member of Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t zu Berlin, and Berlin Institute of Health, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spittel</LastName><ForeName>Susanne</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Centre for ALS and other motor neuron disorders, Charit&#xe9; - Universit&#xe4;tsmedizin Berlin, corporate member of Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t zu Berlin, and Berlin Institute of Health, Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ambulanzpartner Soziotechnologie APST GmbH, Westhafenstr. 1, 13353, Berlin, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>09</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Neurol</MedlineTA><NlmUniqueID>100968555</NlmUniqueID><ISSNLinking>1471-2377</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance></Chemical><Chemical><RegistryNumber>19GBJ60SN5</RegistryNumber><NameOfSubstance UI="D002185">Cannabidiol</NameOfSubstance></Chemical><Chemical><RegistryNumber>7J8897W37S</RegistryNumber><NameOfSubstance UI="D013759">Dronabinol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002185" MajorTopicYN="N">Cannabidiol</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013759" MajorTopicYN="N">Dronabinol</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009128" MajorTopicYN="N">Muscle Spasticity</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017060" MajorTopicYN="N">Patient Satisfaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">CBD</Keyword><Keyword MajorTopicYN="N">Cannabidiol</Keyword><Keyword MajorTopicYN="N">Net promotor score</Keyword><Keyword MajorTopicYN="N">Patient experience</Keyword><Keyword MajorTopicYN="N">Spasticity</Keyword><Keyword MajorTopicYN="N">THC</Keyword><Keyword MajorTopicYN="N">Tetrahydrocannabinol</Keyword><Keyword MajorTopicYN="N">Treatment satisfaction questionnaire for medication</Keyword></KeywordList><CoiStatement>This work was supported Almirall Hermal GmbH, the manufacturer of Tetrahydrocannabinol/Cannabidiol (THC:CBD). TM and CM are founders of the internet platform Ambulanzpartner and hold shares of Ambulanzpartner Soziotechnologie APST GmbH. TM received consultancy fees from Cytokinetics, Biogen, Mitsubishi Tanabe, TEVA and Desitin Arzneimittel GmbH.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>4</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>8</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>9</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>9</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>12</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31493784</ArticleId><ArticleId IdType="pmc">PMC6732193</ArticleId><ArticleId IdType="doi">10.1186/s12883-019-1443-y</ArticleId><ArticleId IdType="pii">10.1186/s12883-019-1443-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>van Es MA, Hardiman O, Chio A, Al-Chalabi A, Pasterkamp RJ, Veldink JH, van den Berg LH. Amyotrophic lateral sclerosis. Lancet. 2017;390:2084&#x2013;2098. doi: 10.1016/S0140-6736(17)31287-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)31287-4</ArticleId><ArticleId IdType="pubmed">28552366</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W, et al. Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017;3:17071. doi: 10.1038/nrdp.2017.71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2017.71</ArticleId><ArticleId IdType="pubmed">28980624</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A, Calvo A, Moglia C, Mazzini L, Mora G. Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study. J Neurol Neurosurg Psychiatry. 2011;82:740&#x2013;746. doi: 10.1136/jnnp.2010.235952.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2010.235952</ArticleId><ArticleId IdType="pubmed">21402743</ArticleId></ArticleIdList></Reference><Reference><Citation>Talman P, Duong T, Vucic S, Mathers S, Venkatesh S, Henderson R, et al. Identification and outcomes of clinical phenotypes in amyotrophic lateral sclerosis/motor neuron disease: Australian National Motor Neuron Disease observational cohort. BMJ Open. 2016;6:e012054. doi: 10.1136/bmjopen-2016-012054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2016-012054</ArticleId><ArticleId IdType="pmc">PMC5051496</ArticleId><ArticleId IdType="pubmed">27694488</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang E, Ghosh N, Yanni D, Lee S, Alexandru D, Mozaffar T. A review of spasticity treatments: pharmacological and interventional approaches. Crit Rev Phys Rehabil Med. 2013;25:11&#x2013;22. doi: 10.1615/CritRevPhysRehabilMed.2013007945.</Citation><ArticleIdList><ArticleId IdType="doi">10.1615/CritRevPhysRehabilMed.2013007945</ArticleId><ArticleId IdType="pmc">PMC4349402</ArticleId><ArticleId IdType="pubmed">25750484</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashworth NL, Satkunam LE, Deforge D. Treatment for spasticity in amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev 2012;2:CD004156. 10.1002/14651858.CD004156.</Citation><ArticleIdList><ArticleId IdType="pubmed">22336799</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenkins TM, Hollinger H, McDermott CJ. The evidence for symptomatic treatments in amyotrophic lateral sclerosis. Curr Opin Neurol. 2014;27:524&#x2013;531. doi: 10.1097/WCO.0000000000000135.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000135</ArticleId><ArticleId IdType="pubmed">25110934</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng L, Khan F, Young CA, Galea M. Symptomatic treatments for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev. 2017;1:CD011776. doi: 10.1002/14651858.CD011776.pub2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD011776.pub2</ArticleId><ArticleId IdType="pmc">PMC6469543</ArticleId><ArticleId IdType="pubmed">28072907</ArticleId></ArticleIdList></Reference><Reference><Citation>Novotna A, Mares J, Ratcliffe S, Novakova I, Vachova M, Zapletalova O, et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols (Sativex), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol. 2011;18:1122&#x2013;1131. doi: 10.1111/j.1468-1331.2010.03328.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2010.03328.x</ArticleId><ArticleId IdType="pubmed">21362108</ArticleId></ArticleIdList></Reference><Reference><Citation>Notcutt W, Langford R, Davies P, Ratcliffe S, Potts R. A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex (nabiximols) Mult Scler J. 2011;18:219&#x2013;228. doi: 10.1177/1352458511419700.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1352458511419700</ArticleId><ArticleId IdType="pubmed">21878454</ArticleId></ArticleIdList></Reference><Reference><Citation>Keating GM. Delta-9-tetrahydrocannabinol/Cannabidiol Oromucosal spray (Sativex&#xae;): a review in multiple sclerosis-related spasticity. Drugs. 2017;77:563&#x2013;574. doi: 10.1007/s40265-017-0720-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-017-0720-6</ArticleId><ArticleId IdType="pubmed">28293911</ArticleId></ArticleIdList></Reference><Reference><Citation>Riva N, Mora G, Sorar&#xf9; G, Lunetta C, Ferraro OE, Falzone Y, et al. Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2019;18:155&#x2013;164. doi: 10.1016/S1474-4422(18)30406-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30406-X</ArticleId><ArticleId IdType="pubmed">30554828</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandenbroucke JP, von Elm E, Altman DG, G&#xf8;tzsche PC, Mulrow CD, Pocock SJ, et al. Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. PLoS Med. 2007;4:e297. doi: 10.1371/journal.pmed.0040297.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.0040297</ArticleId><ArticleId IdType="pmc">PMC2020496</ArticleId><ArticleId IdType="pubmed">17941715</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL. World Federation of Neurology Research Group on Motor Neuron Diseases. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293&#x2013;299. doi: 10.1080/146608200300079536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>https://www.ambulanzpartner.de/. Accessed 5 Apr 2019.</Citation></Reference><Reference><Citation>Jensen MP, McFarland CA. Increasing the reliability and validity of pain intensity measurement in chronic pain patients. Pain. 1993;55:195&#x2013;203. doi: 10.1016/0304-3959(93)90148-I.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0304-3959(93)90148-I</ArticleId><ArticleId IdType="pubmed">8309709</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez CS. Pain measurement in the elderly: a review. Pain Manag Nurs. 2001;2:38&#x2013;46. doi: 10.1053/jpmn.2001.23746.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/jpmn.2001.23746</ArticleId><ArticleId IdType="pubmed">11706769</ArticleId></ArticleIdList></Reference><Reference><Citation>Goulet JL, Buta E, Carroll C, Brandt CA. Statistical models for the analysis of zero-inflated pain intensity numeric rating scale data. J Pain. 2017;18:340&#x2013;348. doi: 10.1016/j.jpain.2016.11.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpain.2016.11.008</ArticleId><ArticleId IdType="pubmed">27919777</ArticleId></ArticleIdList></Reference><Reference><Citation>Goulet JL, Kerns RD, Bair M, Becker W, Brennan P, Burgess DJ, al e. The musculoskeletal diagnosis cohort: Examining pain and pain care among veterans. Pain. 2016;157:1696&#x2013;1703. doi: 10.1097/j.pain.0000000000000567.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/j.pain.0000000000000567</ArticleId><ArticleId IdType="pmc">PMC4949131</ArticleId><ArticleId IdType="pubmed">27023420</ArticleId></ArticleIdList></Reference><Reference><Citation>Reichheld M. Reichheld F, Markey R. the ultimate question 2.0: how net promoter companies thrive in a customer-driven world. Boston: Harvard Business Review Press; 2011. The measure of success; pp. 45&#x2013;60.</Citation></Reference><Reference><Citation>http://www.netpromotersystem.com/. Accessed 5 Apr 2019.</Citation></Reference><Reference><Citation>Atkinson MJ, Sinha A, Hass SL, Colman SS, Kumar RN, Brod M, Rowland CR. Validation of a general measure of treatment satisfaction, the treatment satisfaction questionnaire for medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes. 2004;2:12. doi: 10.1186/1477-7525-2-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1477-7525-2-12</ArticleId><ArticleId IdType="pmc">PMC398419</ArticleId><ArticleId IdType="pubmed">14987333</ArticleId></ArticleIdList></Reference><Reference><Citation>Atkinson M, Kumar R, Cappelleri JC, Hass SL. Hierarchical construct validity of the treatment satisfaction questionnaire for medication (TSQM version II) among outpatient pharmacy consumers. Value Health. 2005;8(Suppl 1):S9&#x2013;S24. doi: 10.1111/j.1524-4733.2005.00066.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1524-4733.2005.00066.x</ArticleId><ArticleId IdType="pubmed">16336491</ArticleId></ArticleIdList></Reference><Reference><Citation>Bharmal M, Payne K, Atkinson MJ, Desrosiers MP, Morisky DE, Gemmen E. Validation of an abbreviated treatment satisfaction questionnaire for medication (TSQM-9) among patients on antihypertensive medications. Health Qual Life Outcomes. 2009;7:36. doi: 10.1186/1477-7525-7-36.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1477-7525-7-36</ArticleId><ArticleId IdType="pmc">PMC2678998</ArticleId><ArticleId IdType="pubmed">19397800</ArticleId></ArticleIdList></Reference><Reference><Citation>Funke A, Spittel S, Grehl T, Grosskreutz J, Kettemann D, Petri S, et al. Provision of assistive technology devices among people with ALS in Germany: a platform-case management approach. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19:342&#x2013;350. doi: 10.1080/21678421.2018.1431786.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2018.1431786</ArticleId><ArticleId IdType="pubmed">29382225</ArticleId></ArticleIdList></Reference><Reference><Citation>Milinis K, Tennant A, Mills RJ, Al-Chalabi A, Burke G, Dick DJ, et al. Development and validation of spasticity index-amyotrophic lateral sclerosis. Acta Neurol Scand. 2018;138:47&#x2013;54. doi: 10.1111/ane.12910.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ane.12910</ArticleId><ArticleId IdType="pubmed">29468643</ArticleId></ArticleIdList></Reference><Reference><Citation>Baldinger R, Katzberg HD, Weber M. Treatment for cramps in amyotrophic lateral sclerosis/motor neuron disease. Cochrane database Syst rev. 2012. p. CD004157.</Citation><ArticleIdList><ArticleId IdType="pubmed">22513921</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Kurent J, Ludolph A. Drug therapy for pain in amyotrophic lateral sclerosis or motor neuron disease. Cochrane Database Syst Rev. 2013;6:CD005226.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7264989</ArticleId><ArticleId IdType="pubmed">23740607</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander SP. Therapeutic potential of cannabis-related drugs. Prog Neuro-Psychopharmacol Biol Psychiatry. 2016;64:57&#x2013;66. doi: 10.1016/j.pnpbp.2015.07.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pnpbp.2015.07.001</ArticleId><ArticleId IdType="pubmed">26216862</ArticleId></ArticleIdList></Reference><Reference><Citation>Aviram J, Samuelly-Leichtag G. Efficacy of cannabis-based medicines for pain management: a systematic review and meta-analysis of randomized controlled trials. Pain Physician. 2017;20:E755&#x2013;E796.</Citation><ArticleIdList><ArticleId IdType="pubmed">28934780</ArticleId></ArticleIdList></Reference><Reference><Citation>DasMahapatra P, Raja P, Gilbert J, Wicks P. Clinical trials from the patient perspective: survey in an online patient community. BMC Health Serv Res. 2017. 10.1186/s12913-017-2090-x.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5327530</ArticleId><ArticleId IdType="pubmed">28241758</ArticleId></ArticleIdList></Reference><Reference><Citation>Melissant H, Verdonck-de Leeuw I, Lissenberg-Witte B, Konings IR, Cuijpers P, Van Uden-Kraan CF. &#x2018;Oncokompas&#x2019;, a web-based self-management application to support patient activation and optimal supportive care: a feasibility study among breast cancer survivors. Acta Oncol. 2018;57:924&#x2013;934. doi: 10.1080/0284186X.2018.1438654.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/0284186X.2018.1438654</ArticleId><ArticleId IdType="pubmed">29451059</ArticleId></ArticleIdList></Reference><Reference><Citation>Weber M, Goldman B, Truniger S. Tetrahydrocannabinol (THC) for cramps in amyotrophic lateral sclerosis: a randomised, double-blind crossover trial. J Neurol Neurosurg Psychiatry. 2010;81:1135&#x2013;1140. doi: 10.1136/jnnp.2009.200642.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2009.200642</ArticleId><ArticleId IdType="pubmed">20498181</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer R, Spittel S, Steinfurth L, Funke A, Kettemann D, M&#xfc;nch C, et al. Patient-reported outcome of physical therapy in amyotrophic lateral sclerosis: observational online study. JMIR Rehabil Assist Technol. 2018;5:e10099. doi: 10.2196/10099.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/10099</ArticleId><ArticleId IdType="pmc">PMC6256108</ArticleId><ArticleId IdType="pubmed">30425026</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>